Immutep - LAG-3 progress in-house and via partners
Immutep has reported encouraging progress from its in-house and partnered programs over the past few months. Interim data from the TACTI-mel combo...
53 Views
Immutep - LAG-3 progress in-house and via partners
Immutep has reported encouraging progress from its in-house and partnered programmes over the past few months. Interim data from the TACTI-mel...
50 Views
Immutep - Merck collaboration opens new opportunities
Immutep has entered a clinical trial collaboration and supply agreement with Merck & Co (MSD) for a Phase II study to evaluate eftilagimod...
71 Views
Immutep - Merck collaboration opens new opportunities
Immutep has entered a clinical trial collaboration and supply agreement with Merck & Co (MSD) for a Phase II study to evaluate eftilagimod...
80 Views
Immutep - Encouraging LAG-3 combo data at SITC
Prima BioMed has changed its name to Immutep Limited following shareholder approval in November. It reported an encouraging 33% preliminary...
77 Views